Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run? [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
reached its randomization target of 555 subjects, while simultaneously reporting third-quarter revenue of US$14.54 million and a net loss of US$69.42 million for 2025. An interesting insight is that, despite year-over-year declines in revenue and higher net losses, the company recorded strong patient retention and adherence in its clinical studies and maintains a cash runway into 2028. We'll now explore how achieving enrollment goals in the SOL-R trial could influence Ocular Therapeutix's broader investment narrative and growth opportunities. Find companies with promising cash flow potential yet trading below their fair value Ocular Therapeutix Investment Narrative Recap Shareholders in Ocular Therapeutix are essentially wagering on the approval and commercial success of AXPAXLI in wet AMD, making clinical trial progress and regulatory outcomes crucial. The recent news that the SOL-R trial hit its randomization goal bolsters the most important short-term catalyst, top-line d
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
- Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDRGlobeNewswire
- Ocular Therapeutix (NASDAQ:OCUL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCUL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix (NASDAQ:OCUL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCUL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- OCUL's page on the SEC website